Acne Vulgaris, Hair Loss, and Skin Conditions: Causes, Treatments, and What Actually Works

Acne vulgaris is a chronic inflammatory disorder of the hair follicle and its attached oil gland (the pilosebaceous unit). Male pattern hair loss, female pattern hair loss, telogen effluvium, and alopecia areata are four distinct hair-loss conditions that are frequently confused with each other because they all present as "losing hair," but they have different causes, different courses, and different treatments. This article covers all five conditions together because they share overlapping biology (androgens drive both acne and pattern hair loss) and because patients often need to tell them apart before choosing a treatment.

The useful question for a new patient is rarely "which acne or hair-loss drug is strongest." It is which mechanism and pattern matches what is actually happening on the skin or scalp, because a drug that works well for androgen-driven hair thinning (minoxidil, finasteride) does nothing for an autoimmune patch of alopecia areata, and a drug that clears autoimmune alopecia (a JAK inhibitor) is not indicated for ordinary pattern thinning.

Direct answer, with scope: Acne vulgaris is treated with topical retinoids, benzoyl peroxide, time-limited oral antibiotics, hormonal therapy, or oral isotretinoin depending on severity, all of which are FDA-approved options with decades of trial support. Male and female pattern hair loss respond to topical minoxidil (FDA-approved for both sexes) and, in men, oral finasteride (FDA-approved); spironolactone and oral finasteride in women are off-label but guideline-supported in specific circumstances. Telogen effluvium is usually self-limited once the trigger resolves and does not require drug therapy. Alopecia areata now has two FDA-approved systemic drugs (baricitinib and ritlecitinib) for severe disease, both JAK inhibitors carrying class-wide black-box warnings. None of these five conditions is diagnosed or safely dosed from a written guide; a clinician needs to see the pattern.

What acne vulgaris is and what drives it

Acne is not a single pimple. It ranges from non-inflammatory blackheads and whiteheads to deep, scarring nodules. Four mechanisms intersect: excess sebum production, abnormal shedding of cells inside the follicle (hyperkeratinization), colonization by the bacterium Cutibacterium acnes, and the inflammatory response that follows.

The sebaceous gland responds to androgens, particularly dihydrotestosterone (DHT) and dehydroepiandrosterone sulfate (DHEAS). This response explains the sharp increase in acne breakouts during puberty and the cyclical flaring that many women experience in the luteal phase, when androgen levels relative to other hormones change. Acne runs in families, with parental severity correlating to increased risk in children, though the degree of this association differs between studies and should be understood as population-dependent rather than a universal figure.

Diet has a modest, debated role. Several observational studies and small trials have linked high-glycemic-load diets to more severe acne, and some cohort studies report a weaker association with dairy, particularly skim milk. The effect sizes reported are generally small, and diet alone rarely clears moderate-to-severe acne.

Grading (used to match treatment intensity):

• Grade I (comedonal): blackheads and whiteheads only
• Grade II (mild-moderate): comedones plus scattered papules and pustules
• Grade III (moderate-severe): numerous papules, pustules, and nodules
• Grade IV (nodulocystic/conglobate): deep, interconnected nodules with high scarring risk

Acne treatment: what is FDA-approved, what is guideline-recommended, and what is off-label

Topical retinoids (tretinoin, adapalene, tazarotene) are considered by AAD guidance to be appropriate for nearly all acne severities because they normalize follicular shedding and have anti-inflammatory activity. This is a paraphrase of guideline language, not a direct quotation, and the exact wording should be checked against the current AAD guideline before it is republished as a quote.

Benzoyl peroxide (BPO), typically 2.5-10%, kills C. acnes through oxidative mechanisms and does not select for antibiotic-resistant strains the way antibiotics alone can. Pairing BPO with a topical antibiotic (clindamycin or erythromycin) is standard practice specifically because BPO limits resistance development.

Oral antibiotics (commonly doxycycline or minocycline) are used for moderate-to-severe inflammatory acne. Guideline bodies generally recommend limiting continuous oral antibiotic courses to a few months to reduce resistance pressure; readers should confirm the current recommended duration with a prescriber rather than assume a fixed number of weeks.

Oral isotretinoin is the most effective single agent for severe nodulocystic acne and can produce durable remission after one full course in a large share of patients, though the exact remission percentage varies by study and dosing protocol. Isotretinoin is an FDA-approved drug, but because it is teratogenic, prescribers and patients in the US must enroll in the iPLEDGE REMS program, which requires confirmed negative pregnancy testing before and during treatment for anyone with reproductive potential. Details of current program requirements are maintained by the FDA. (FDA REMS program page)

Hormonal therapy targets the androgen driver directly. Combined oral contraceptives containing ethinyl estradiol with norgestimate, norethindrone acetate, or drospirenone carry FDA approval specifically for acne in women, and systematic reviews of randomized trials have found they reduce inflammatory and comedonal lesion counts compared with placebo. Spironolactone, an androgen-receptor blocker, is used off-label for hormonal acne in women, typically presenting as jawline and chin breakouts that flare around menstruation; it is not FDA-approved for this indication and is not appropriate for use in men because of feminizing side effects at effective doses.

Male pattern hair loss (androgenetic alopecia)

Male pattern hair loss (MPHL) is progressive miniaturization of genetically susceptible scalp follicles, driven by DHT binding to androgen receptors in the follicle's dermal papilla. Testosterone is converted to DHT locally by the enzyme 5-alpha reductase type II. Over time this shortens the growth (anagen) phase, produces progressively finer hairs, and eventually follicles stop producing visible hair. The Hamilton-Norwood scale (stages I-VII) is the standard way clinicians describe the pattern, from temple recession to complete vertex balding with a peripheral rim.

Population prevalence estimates vary by study and age cutoff, but MPHL is common: roughly half of men show some degree of it by mid-life, with prevalence continuing to rise with age. Exact percentages by decade differ across surveys and should not be treated as precise without checking the specific study.

FDA-approved treatments:

• Oral finasteride 1 mg/day inhibits 5-alpha reductase type II and lowers scalp DHT substantially. Randomized trial data (dating to the original pivotal trials in the late 1990s) showed meaningful increases in hair count versus placebo at one year, though the exact hair-count figures reported online vary by trial and should be checked against the original publication. Sexual side effects (reduced libido, erectile dysfunction) occur in a minority of men and generally resolve after stopping the drug, though persistent symptoms after discontinuation have been reported and should be discussed with a prescriber. Finasteride also lowers PSA, which matters for interpreting prostate cancer screening in men who take it.
• Topical minoxidil 5% (solution or foam) prolongs the anagen phase and increases follicular size through a mechanism that is not fully established. Higher-concentration formulations have outperformed lower ones in head-to-head trials.

Off-label option: low-dose oral minoxidil (roughly 0.625-2.5 mg/day, sometimes higher in specialist protocols) has become popular as an alternative to topical minoxidil, and some trials report it performs at least comparably to topical minoxidil, with facial or body hair growth (hypertrichosis) as the most common side effect. Oral minoxidil is not FDA-approved for hair loss; it is an off-label use of a drug approved for hypertension, and cardiovascular effects (fluid retention, reflex tachycardia) should be discussed before starting it, particularly in patients with cardiac disease.

Hair transplantation (follicular unit excision or strip harvesting) is a surgical option for men with stable, advanced hair loss. Transplanted follicles keep their donor-site resistance to DHT, but continuing medical therapy is generally recommended to slow loss in the untransplanted areas.

Female pattern hair loss (androgenetic alopecia in women)

Female pattern hair loss (FPHL) has a different pattern than the male form: diffuse thinning over the crown with a widening central part, graded by the Ludwig scale, and the frontal hairline is typically preserved. That preserved hairline is a useful clue that distinguishes FPHL from telogen effluvium, where shedding is more uniformly diffuse.

Serum androgen levels are often normal in women with FPHL, which suggests that in many cases the follicle's sensitivity to androgen, not the amount of circulating androgen, is what matters.

Topical minoxidil (2% or 5%) is the only FDA-approved topical drug for FPHL. The 2% solution used twice daily has the longest safety track record; the 5% foam used once daily has also been studied and may improve adherence because of the simpler regimen; trials comparing the two formulations have generally found similar effectiveness.

Spironolactone (off-label) is widely used, and international dermatology guidelines have described it as a reasonable second-line option for women with FPHL, particularly those who also have hormonal acne or elevated androgens. It blocks the androgen receptor and has weak 5-alpha reductase inhibiting activity. Potassium should be monitored, especially in patients also taking an ACE inhibitor or ARB.

Finasteride (off-label) is used in post-menopausal women at doses generally higher than the male dose. It is contraindicated in anyone who could become pregnant because of teratogenic risk.

Low-level laser therapy (LLLT) devices have received FDA clearance as medical devices (a lower evidentiary bar than drug approval) for hair growth, and small randomized trials have reported modest density improvements over sham devices. This is device-level evidence, not the same tier as a pivotal drug trial.

A first-visit decision framework for pattern hair thinning

Before starting any hair-loss medication, the pattern and a short lab workup change what should happen next. This is a general framework, not a substitute for an in-person or synchronous clinical evaluation.

Baseline labs reasonable before starting FPHL pharmacotherapy: TSH, ferritin, and, when the history suggests hyperandrogenism (irregular cycles, hirsutism, cystic acne), total and free testosterone and DHEAS. A ferritin at the low end of normal is a plausible, correctable contributor to shedding, though correcting it does not reliably reverse androgenetic miniaturization once it has occurred, and evidence for zinc or vitamin D supplementation as standalone hair-loss treatment is limited.

Exceptions that change the plan: pregnancy or plans for pregnancy rule out finasteride and make spironolactone and oral minoxidil questions for a prescriber; a cardiac history should be flagged before oral minoxidil is considered; and any rapidly expanding bald patch, scarring, or scalp pain should prompt evaluation rather than a trial of over-the-counter minoxidil, because scarring alopecias (including folliculitis decalvans and dissecting cellulitis of the scalp) can cause permanent follicle loss if treatment is delayed.

Telogen effluvium

Telogen effluvium (TE) happens when a physiological or psychological stressor pushes an abnormally large share of follicles out of the growth phase and into the resting (telogen) phase at once. Weeks later, those hairs shed together, producing a shedding episode that feels sudden and alarming even though the trigger occurred one to several months earlier.

Common triggers include childbirth (postpartum TE is the most common presentation), major surgery or general anesthesia, high fevers, thyroid dysfunction in either direction, severe caloric restriction, abrupt discontinuation of combined oral contraceptives, and significant psychological stress. A large cohort study following COVID-19 infection found an increased risk of inflammatory skin conditions afterward; this study examined inflammatory dermatoses broadly rather than telogen effluvium specifically, so it supports viral illness as a plausible trigger category rather than a precise telogen effluvium risk figure. (cohort study, COVID-19 and inflammatory dermatoses)

A simple bedside check is the hair pull test: grasping a small bundle of hairs near the scalp and pulling gently. Extracting several club-shaped (white-bulbed) hairs supports a diagnosis of active shedding. Trichoscopy showing diffuse thinning of shaft caliber without the miniaturization pattern of androgenetic alopecia helps separate TE from AGA when the picture is unclear.

TE typically resolves within a few months once the trigger is identified and corrected, and most cases do not require drug therapy. When shedding persists beyond about six months (chronic TE), reassessment for a persistent cause, such as unrecognized thyroid disease or iron deficiency, is reasonable. Topical minoxidil is sometimes used to accelerate regrowth in prolonged cases, but published trial evidence specific to chronic telogen effluvium is limited, and this remains an off-label, less-established use.

Alopecia areata

Alopecia areata (AA) is an autoimmune condition in which T cells attack the hair follicle during its growth phase, producing sudden, well-defined, non-scarring bald patches. It ranges from a single small patch to complete scalp hair loss (alopecia totalis) or loss of all body hair (alopecia universalis). Nail pitting is a supportive clinical finding in a meaningful subset of patients.

Intralesional corticosteroids remain first-line for patchy disease affecting a limited area of the scalp, typically given as small injections repeated every several weeks. Regrowth rates reported in the literature for this approach are generally favorable for limited patchy disease, though exact response percentages vary by series and severity. Repeated injections carry a real risk of local skin thinning (atrophy) if volume and depth are not controlled.

Topical corticosteroids and topical minoxidil are adjunct, lower-evidence options, sometimes used for patients who cannot tolerate injections or have very small patches.

JAK inhibitors are the newest and most consequential development in this condition. Baricitinib received FDA approval for severe alopecia areata in 2022, and ritlecitinib followed with FDA approval in 2023 for patients aged 12 and older with severe disease; both were the first systemic drugs approved specifically for this indication (dates should be confirmed against the current FDA label before republishing, since approved ages and dosing can be updated). Both drugs carry the class-wide FDA black-box warning shared by JAK inhibitors, covering serious infections, malignancy, and major adverse cardiovascular events, and both require baseline lab screening (complete blood count, lipid panel, liver function tests, and tuberculosis screening) before starting. In their pivotal trials, a substantially higher proportion of treated patients achieved meaningful scalp regrowth compared with placebo at roughly eight to nine months of treatment; readers who need the exact response percentages for clinical decision-making should check the current FDA label or the primary trial publication rather than a secondary summary. These drugs are reserved for severe disease, not mild or moderate patchy AA.

Where acne and hair loss overlap

Acne and androgenetic hair loss share hormonal biology rather than being separate accidents of the same person. Women with polycystic ovary syndrome (PCOS) commonly have all three of acne, FPHL, and excess body hair (hirsutism) driven by the same underlying androgen excess. This is why a single drug, spironolactone, can meaningfully help both the acne and the hair thinning in the same patient, which is one practical reason it is prescribed so often for women with this combination.

Isotretinoin, the acne drug, can itself cause temporary telogen-effluvium-type shedding during treatment in a meaningful minority of patients; this generally reverses after the course ends and is a known, disclosed side effect rather than a sign the drug is failing.

Scalp folliculitis and its severe form, folliculitis decalvans, are inflammatory conditions that, unlike ordinary acne, can permanently destroy hair follicles if untreated, because the inflammation scars the follicle rather than just irritating it. A related and often confused condition is dissecting cellulitis of the scalp, part of the same follicular-occlusion family as severe acne. A recent case-based treatment report described using isotretinoin combined with oral antibiotics and a biologic (bimekizumab) for refractory dissecting cellulitis; this reflects an emerging treatment strategy from a small clinical series rather than an established first-line regimen, and it underscores that scarring scalp conditions need dermatologic evaluation rather than over-the-counter management. (treatment strategy report, refractory dissecting cellulitis of the scalp)

Acne scarring

Acne scars form when deep inflammation disrupts the skin's collagen structure. The three common morphologic types are ice-pick scars, rolling scars, and boxcar scars, and they respond to different procedures. Starting effective acne treatment earlier in the course of disease is generally associated with lower scarring risk in observational data, though the exact magnitude of that risk reduction varies by study and should not be quoted as a fixed multiplier.

Treatment options for established scars include:

• Subcision for tethered rolling scars, to release fibrous bands under the skin
• Fractional CO2 laser for ice-pick and boxcar scars, usually over several sessions
• Chemical reconstruction of skin scars (CROSS) using high-concentration trichloroacetic acid for deep ice-pick scars
• Microneedling, with or without platelet-rich plasma, for mild-to-moderate rolling scars

No single technique works for every scar type; combining approaches matched to the scar morphology tends to produce better results than any single modality alone.

When to seek care rather than self-manage

• Acne that has not improved after a full, consistent course of topical therapy (generally several months)
• Hair shedding that is clearly heavier than usual and persists beyond about six months
• A bald patch that is expanding rather than stable
• Hair loss accompanied by fatigue, unexplained weight change, or temperature intolerance, which raises the possibility of thyroid disease
• Alopecia areata that is worsening despite topical treatment
• Any scalp pain, pus, or scarring, which suggests an inflammatory scarring process rather than ordinary pattern hair loss or telogen effluvium

Chronic skin disease also carries a real quality-of-life cost, particularly in adolescents, where visible acne has been associated with effects on self-esteem and social functioning in recent research examining chronic skin disease and adolescent quality of life; this supports treating acne as more than a cosmetic issue, though the specific magnitude of psychosocial impact varies across studies and populations. (chronic skin disease and adolescent quality of life)

A dermatologist can use trichoscopy, a trichogram, or a scalp biopsy to settle an uncertain diagnosis. Telehealth evaluation using photographs can reasonably manage straightforward mild-to-moderate acne and early, uncomplicated pattern hair loss, but photographic diagnosis has real limits compared with an in-person exam, and it is not an appropriate substitute for synchronous or in-person evaluation when the picture is atypical, when scarring or rapid progression is present, or when isotretinoin or a systemic immunosuppressant is being considered.

Evidence boundary

Established: topical retinoids, benzoyl peroxide, oral antibiotics for a limited course, hormonal therapy, and isotretinoin are all FDA-approved or guideline-supported acne treatments with a long trial record. Topical minoxidil is FDA-approved for both male and female pattern hair loss, and oral finasteride is FDA-approved for male pattern hair loss. Baricitinib and ritlecitinib are FDA-approved for severe alopecia areata and carry class-wide black-box warnings.

Plausible but less settled: oral low-dose minoxidil for pattern hair loss, spironolactone and finasteride for female pattern hair loss, and topical minoxidil for chronic telogen effluvium are all widely used and guideline-referenced but remain off-label uses supported by a smaller or more mixed trial base than the FDA-approved options above.

Not established from current evidence: precise numeric claims (exact hair-count increases, exact remission percentages, exact scarring-risk multipliers, exact diagnostic-concordance percentages for telehealth) circulate widely online but trace back to individual trials with specific populations and methods. These numbers should be verified against the current primary publication or FDA label before being used to counsel an individual patient, and none of them should be read as a guarantee of an individual's outcome.